Odyssey Therapeutics 1 article

One scientific anchor for Odyssey Therapeutics is immunology drug discovery, and another is RIPK2 scaffolding inhibition; together they define its role as a biopharmaceutical company. The scientific portfolio of Odyssey Therapeutics brings together innate immune signaling modulation, IRAK4 scaffolding biology and autoimmune disease small molecules, preserving a specific mechanistic identity. Within the taxonomy, Odyssey Therapeutics is broader than any one medicine and is additionally characterized by inflammatory pathway target discovery.

Biotech Companies & Pipelines

October 1, 2026, 9:45 AM · 3 mins read

HBM Healthcare Investments forecasts sharp profit jump as private biotech deals pay off

HBM Healthcare Investments expects a half-year profit of CHF 177 million, fueled by big gains in private biotech holdings and major exits, even as listed assets remain volatile.